Research Overview by Dr. Katie Golden, MD: C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions (V. Mohanan et al., https://doi.org/10.1126/science.aan0814)

With the recent technical advances in genetic sequencing, a number of genes and polymorphisms have been identified that confer increased risk for Inflammatory Bowel Disease (IBD). Scientific research has not yet elucidated, however, the mechanisms through which these genes promote the pathophysiology of IBD. In this paper, investigators studied the specific gene C1orf106, and describe […]

Read more

Research Overview by Dr. Katie Golden MD: Dynamics of Metatranscription in the Inflammatory Bowel Disease Gut Microbiome (Schirmer M., et al., Nat Microbiol. 2018 Jan 8)

Scientists have identified several genetic mutations implicated in Inflammatory Bowel Disease (IBD), and recent research has focused on defining those environmental factors that affect expression of these genes. Over the past decade, investigators have to come to realize that the gut microbiome plays a central role in IBD development and progression. The relationship between variations […]

Read more

[Center Publication] C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. V Mohanan et al., http://science.sciencemag.org/content/early/2018/01/31/science.aan0814.full

Abstract Polymorphisms in C1orf106 are associated with increased risk of inflammatory bowel disease (IBD). However, the function of C1orf106 and the consequences of disease-associated polymorphisms are unknown. Here we demonstrate that C1orf106 regulates adherens junction stability by regulating the degradation of cytohesin-1, a guanine nucleotide exchange factor that controls activation of ARF6. By limiting cytohesin-1-dependent ARF6 activation, […]

Read more

[Center Publication] Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. M. Schirmer et al., Nat Microbiol. 2018 Jan 8

Abstract Inflammatory bowel disease (IBD) is a group of chronic diseases of the digestive tract that affects millions of people worldwide. Genetic, environmental and microbial factors have been implicated in the onset and exacerbation of IBD. However, the mechanisms associating gut microbial dysbioses and aberrant immune responses remain largely unknown. The integrative Human Microbiome Project seeks to close these gaps by examining […]

Read more

Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.

Ananthakrishnan AN et al., Cell Host Microbe. 2017 May 10;21(5):603-610.e3. doi: 10.1016/j.chom.2017.04.010. The gut microbiome plays a central role in inflammatory bowel diseases (IBDs) pathogenesis and propagation. To determine whether the gut microbiome may predict responses to IBD therapy, we conducted a prospective study with Crohn’s disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizumab). Disease […]

Read more

Top